Investor Presenta,on Albert D. Friesen, PhD Chair & CEO Dawson Reimer President & COO March 31, 2015
Disclaimer This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for Medicure Inc., business and operational results. By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, product recalls, competition from similar products and other factors including those risks and uncertainties identified above, and those contained in the Company s most recent MD&A and Form 20F. Medicure Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law. 2
Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombo,c cardiovascular events (combined endpoint of death, myocardial infarc,on, or refractory ischemia/repeat cardiac procedure) in pa,ents with non- ST eleva,on acute coronary syndrome (NSTE- ACS). Dosage and Administra/on: High- Dose Bolus Regimen: Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In pa,ents with CrCl 60 ml/min, use the full bolus and halve the maintenance infusion. Contraindica/ons: Known hypersensi,vity to any component of AGGRASTAT; History of thrombocytopenia with prior exposure to AGGRASTAT; Ac,ve internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month Warnings and Precau/ons: AGGRASTAT can cause serious bleeding. If bleeding cannot be controlled discon,nue AGGRASTAT; Thrombocytopenia: Discon,nue AGGRASTAT and heparin Adverse Reac/ons: Bleeding is the most commonly reported adverse reac,on 3
$3.5 $3.0 $2.5 $2.0 $1.5 $1.0 $0.5 $0.0 Q1 Q2 Aggrastat Quarterly Net Product Sales (CDN Millions) Q3 Q4 Q1 2013 2014 Medicure Inc. Overview Q2 Q3 Q4 Q1 4
Future Value Drivers Additional regulatory studies Penetrate Angiomax & Reopro Market Established API Manufacture Transdermal Aggrastat is in Development Tardoxal New Product in Development for Motion Disorders * TARDOXAL is an experimental product that is not approved by the FDA * AGGRADERM is an experimental product that is not approved by the FDA 5
Launched by Merck in 1998 U.S. rights acquired by Medicure in 2006 I.V. platelet inhibitor; binds the GP IIb/IIIa receptor Indicated for Acute Coronary Syndrome (ACS) 41% reduction in death and MI in high-risk patients* Patent expiration: June 2023 New FDA Approved High Bolus Dosing Regimen * PRISM PLUS Investigators, N Engl J Med. 1998:1488-1497. 6
Competitive Positioning of Aggrastat 7
New US Hospitals Using Aggrastat 8
New Commercial Model Weekly Bag Demand 9
$3,500 GPI Acquisition Costs $3,000 $2,500 $2,000 $1,500 $1,000 $500 $0 $3,126.12 Reopro Aggrastat: 25 µg/kg bolus + 0.15 µg/kg/min Integrilin: 2x180 µg/kg bolus + 2.0 µg/kg/min Reopro: 0.25 mg/kg bolus + 0.125 µg/kg/min $1,306.44 Integrilin $517.81 Aggrastat 12-hr Infusion (90 kg patient) US healthcare system is financially stressed Integrilin often one of the largest pharmacy line items Typical hospital savings: $50,000 - $500,000 / year Required Units: US $; Based on WAC pricing as of January 2015. Cost of heparin has not been included. Cost comparisons do not imply comparable efficacy, safety or product interchangeability. Aggrastat, Reopro (abciximab), and Integrilin (eptifibatide) have not been compared in head-to-head clinical trials. Please refer to prescribing information for approved indications for all products. 10
Aggrastat Price vs. Angiomax $2,000 $1,781.60 Angiomax 2001 2013 Angiomax replaced > 1/2 of GPIs in US $1,500 $1,000 $500 $890.80 Angiomax $247.29 Aggrastat $247.29 Aggrastat Aggrastat short infusion is alternative to Angiomax Typical hospital savings: $100,000 - $1,500,000 / year $0 Bolus- only Bolus + 2hr infusion Required Units: Angiomax: 0.75 mg/kg bolus + 1.75 mg/kg/h Aggrastat: 25 µg/kg bolus + 0.15 µg/kg/min CV Interven/onal Drugs Total $991.6 million/year 2014 U.S. Gross Sales before discounts; WAC Source: Wolthers Kluwer Health, repor,ng +10% Based on WAC pricing as of January 2015. Cost of heparin has not been included. Cost comparisons do not imply comparable efficacy, safety or product interchangeability. Aggrastat and Angiomax (bivalirudin) have not been compared in head-to-head clinical trials. Please refer to prescribing information for approved indications for products. 11
SAVI PCI Study Design Total 675 patients undergoing PCI (March Enrollment Update: 2/3 Complete) Choice of Oral Anti-Platelet(s) ASA and clopidogrel or prasugrel or ticagrelor I.V. Anti-Thrombin Unfractionated Heparin 50 U/kg 1:1:1 randomization Open-label Tirofiban HDB (short) 25µg/kg bolus + 0.15µg/kg/min infusion during procedure + 1-2 hours Tirofiban HDB (long) 25µg/kg bolus + 0.15µg/kg/min infusion during procedure + 12-18 hours Eptifibatide 180 µg/kg bolus followed by a 2.0 µg/kg/min infusion for 12-18 hours, with a second 180 µg/kg bolus 10 min after the first Percutaneous Coronary Intervention 48 hours following PCI or hospital discharge, whichever comes first Primary Composite Endpoint: Death, MI, utvr or REPLACE-2 major bleeding (non-inferiority) 12
SAVI PCI Clinical Study Aggrastat is the only GPI Approved with Short Infusion Benefit of Short Infusion: Poten,al for reduced bleeding while s,ll maintaining efficacy Fits beier with contemporary medicine & facilitates outpa,ent PCI 0.5 hrs 1-2 hrs 12-24 hrs PCI SAVI PCI Tradi/onal Treatment Dura/on Bolus Delivery 25mcg/kg bolus Maintenance Infusion 0.15mcg/kg/min infusion 13
Apicore Transaction Deal Features: 1. Medicure receives fixed price options to buy 100% ownership until July 2017 2. Medicure receives 6.1% equity (5.3% fully diluted) 3. $22.5 Million share purchase & debt financing of Apicore structured by Medicure 4. Albert Friesen named Chair of Board of Apicore 5. FDA Approved Drugs Press Release: July 3, 2014 Medicure Acquires Minority Position In Pharmaceutical Manufacturer, Apicore Apicore Investors: Signet Healthcare (equity) Knight Therapeutics ($6.25 mm loan) Sanders Morris Harris Inc. (loan) 14
Apicore Background Year Revenue Commercial Products 2012 $5 Million 3 2013 $10.3 Million 3 2014 Not Disclosed 8 Somerset, New Jersey Vadodara, Gujarat, India API Manufacturer & ANDA Developer Complex synthetic chemistry Early & first to file generics Secure, high quality production History: Opened US facility in 2004 First FDA approval in 2006 (Granisetron HCl, post-chemo anti-nausea) Filed DMF for Fondaparinux in 2010 8 successful FDA audits to date (6 in New Jersey, 2 in India) Expanded Indian facility in 2013 15
Business Vision $3.5 Aggrastat Quarterly Net Product Sales (CDN Millions) $3.0 $2.5 To build a large, stable, specialty pharmaceutical company $2.0 $1.5 $1.0 $0.5 $0.0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 To further expand Aggrastat revenue To expand revenue with new commercial products To diversify company value with new products and business areas 2013 2014 16
Cap Structure As of April 27, 2015 Basic Total 12,523,980 Fully Diluted Total 14,494,470 Key Financial Info Expressed in CND Share Price $2.38 Market Cap $29,807,072 Recent Financial Highlights Q1 Net Revenue- $3.3 M *Adjusted EBITA- $ 1.1 M CFPS- $0.06 EPS- $ 0.01 2015 Financial Focus Strengthen balance sheet with increased cash flow from Aggrastat sales Organic growth by investing in sales and marketing *Removing non-cash stock-based compensation expense in the EBITDA 17
Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombo,c cardiovascular events (combined endpoint of death, myocardial infarc,on, or refractory ischemia/repeat cardiac procedure) in pa,ents with non- ST eleva,on acute coronary syndrome (NSTE- ACS). Dosage and Administra/on: High- Dose Bolus Regimen: Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In pa,ents with CrCl 60 ml/min, use the full bolus and halve the maintenance infusion. Contraindica/ons: Known hypersensi,vity to any component of AGGRASTAT; History of thrombocytopenia with prior exposure to AGGRASTAT; Ac,ve internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month Warnings and Precau/ons: AGGRASTAT can cause serious bleeding. If bleeding cannot be controlled discon,nue AGGRASTAT; Thrombocytopenia: Discon,nue AGGRASTAT and heparin Adverse Reac/ons: Bleeding is the most commonly reported adverse reac,on 18
Thank you. Contact a Product Specialist 1.800.509.0544 For More Informa/on www.medicure.com www.aggrastat.com Investor Rela/ons ir@medicure.com 1.888.435.2220 (Ext. 231) Analyst Coverage Andre Uddin Mackie Research 19